TC BioPharm (Holdings) Ltd Stock Price, News & Analysis

TC BioPharm (NASDAQ: TCBP) has advanced negotiations with previously announced acquisition candidates as part of its M&A expansion strategy. The company is focusing on two main areas: Natural Kill cell technologies and CAR-related technologies.

TCBP is prioritizing near-term opportunities in the NK space, exploring allogeneic NK and CAR-NK technologies to expand into autoimmune disease, solid tumors, and combination therapies with TCB008. The company is also pursuing novel CAR technologies to enhance TCB008's efficacy in solid tumors and other cancers, aiming to increase therapeutic use cases and manufacturing site utilization.

Management reports positive progress in discussions with current acquisition targets, focusing on companies with proprietary treatment approaches that complement TCBP's platform.

TC BioPharm (NASDAQ: TCBP) announced shareholders' approval of a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of January 2, 2025, with delivery expected around January 6th. Trading will temporarily halt from January 2, 2025, at 5:00 pm and resume around January 8, 2025, to process the dividend. Nasdaq will adjust the opening price on January 8 to reflect dilution impact.

CEO Bryan Kobel stated this special dividend reflects management's confidence in the company's financial future and is part of their capital management strategy. He anticipates 2025 to be a period of growth and development, focusing on delivering improved shareholder value.

TC BioPharm (NASDAQ: TCBP) has announced and received shareholder approval for a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of the record date of January 2, 2025. The distribution is expected to occur on or about January 6th, 2025.

Trading of TCBP's ADSs will temporarily halt at 5:00 pm on January 2, 2025, and resume on January 7, 2025, allowing the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 7 to account for the dilution impact.

CEO Bryan Kobel emphasized that this special dividend demonstrates management's confidence in the company's financial future and serves as a component of their capital management strategy. He expressed optimism about 2025 being a period of growth and development for the clinical-stage biotechnology company, which develops platform allogeneic gamma-delta T cell therapies for cancer and other indications.

TC BioPharm (NASDAQ: TCBP) reported progress in its ACHIEVE Phase 2b clinical trial, with 3 patients completing the full-dose regimen without drug-related adverse events. The trial evaluates TCB008 in patients with AML or MDS/AML. Current enrollment status: 10 patients received first dose, 9 second dose, 4 third dose, and 3 completed all four doses. Nine patients are in Cohort A (relapsed/refractory patients), and one in Cohort B (remission with detectable residual disease). The trial aims to recruit 14 patients initially in each cohort, with potential for 10 more per cohort, totaling 48 patients. The 5mL TCB008 dose shows good tolerability with no drug-related adverse events.

TC BioPharm (NASDAQ: TCBP) has announced a special dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held by shareholders, subject to shareholder approval. The company will hold a general meeting on December 30, 2024, at 2:00 p.m. (UK time) in Cullen, Scotland. The dividend is expected to be declared on December 30, 2024, with eligibility for shareholders on record as of January 02, 2025.

CEO Bryan Kobel emphasized that this dividend is a reward for shareholder support during challenging market conditions, including what he described as a 'false short and distort campaign.' The specific payment date for ADSs will be announced later.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced a partnership with CareDx (NASDAQ: CDNA) to support the ACHIEVE clinical trial. This phase II, open-label study aims to evaluate the efficacy of TCB008, an allogeneic gamma delta T cell therapy for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

CareDx will use its AlloCell solution for pharmacokinetic analysis to monitor the expansion and persistence of TCB008 in patients. The data collected will help understand the duration and effect of TCB008 in reconstituting the immune system of AML patients. Alison Bracchi, EVP of Clinical Operations at TC BioPharm, highlighted the partnership as a significant milestone in developing TCB008. Marica Grskovic, PhD, CareDx Chief Strategy Officer, emphasized the collaboration's role in advancing allogeneic cell therapy for AML patients.

TC BioPharm (NASDAQ: TCBP) provided an update on its ACHIEVE UK Trial for TCB008, a gamma-delta T cell therapy. Over half of Cohort A patients in Stage One have received treatment, showing positive safety signals at the 5mL dose (230 million Gamma Delta T-Cells) with no serious adverse events reported.

The company plans to increase dosage up to 819 million cells to identify optimal levels. Currently, 4 UK clinical sites are recruiting patients, with 2 more sites expected in H1 2025. The trial includes two patient groups: Cohort A (failed standard treatments) and Cohort B (residual disease after initial remission). The company plans to implement increased TCB008 doses alongside a scaled-up manufacturing process in 2025.

TC BioPharm has been awarded a $250,000 non-dilutive grant from ScaleReady's G-Rex® Grant Program to support TCB008 manufacturing process optimizations over the next 18 months. The company aims to increase yields while reducing manufacturing costs by over 80%. The grant will help expedite process optimizations, allowing for expanded yields with a shortened manufacturing process in the first half of 2025, which is 12 months ahead of schedule. The optimizations will increase TCB008 production rate at the existing Maxim Park facility without increasing overhead costs.

TC BioPharm (NASDAQ: TCBP) reported significant progress in 2024, highlighting achievements in its ACHIEVE UK trial for TCB008, where 8 patients have been dosed, including 2 completing all 4 doses. The company expanded trial sites, including Guy's and St. Thomas Hospital, with two more sites planned for Q1 2025. Key developments include signing two LOIs for acquisitions, initiating Mpox treatment research, and forming an AI partnership for donor screening. Financial highlights include a 50% reduction in Q1 cash burn and raising $8 million in Q3. Manufacturing improvements have increased treatment capacity from 52 to over 1,000 patients annually, with an 85% cost reduction per treatment.